The intracellular signal that drives T helpers or CD8+ cells to over express TIM3 is not clear, but its co-expression with PD-1 on tumor specific CD8+ T cells makes it an important future candidate for combined immunotherapy [46–48]. This evidence concerns the gene HAVCR2 and neoplasm.